Boehringer Ingelheim will pay Sino Biopharmaceutical $358 million upfront and near-term for options on six biologic oncology programs, deepening a partnership that began in 2024.
|Articles|June 3, 2015
Baxter Partners with Mayo Clinic and Velocity to Form New Company
Author(s)BioPharm International Editors
Baxter announces that it will partner with Mayo Clinic and Velocity Pharmaceutical to form Vitesse Biologics, a Baxalta-managed company focused on immunology, hematology, and oncology.
Advertisement
On June 1, 2015, Baxter Ventures, the Mayo Clinic, and Velocity Pharmaceutical Development announced the formation of Vitesse Biologics, a company that will focus on the development of antibody and protein-based therapeutics in immunology, hematology, and oncology. Baxalta, which was named Baxter International’s new biopharmaceutical arm in
The new company was developed as a collaborative effort to advance therapies quickly. According to a press release, Baxter BioScience will “provide global commercialization, antibody and protein development, and manufacturing;” Mayo Clinic will execute Phase I clinical trials; and Velocity “will be responsible for target identification, selection of early stage drug candidates, and will lead the design and execution of pre-clinical and clinical protocols.”
"By creating Vitesse, our business is executing on a new concept in early stage R&D by leveraging the expertise of industry-leading partners to accelerate the identification and development of novel biologic treatments that could eventually contribute to unmet patient needs while enhancing the Baxalta commercial portfolio,” said Ludwig N. Hantson, PhD, president of Baxter BioScience, in a press release.
Source:
Baxalta
Advertisement
Related to this article
Teva will commercialize etanercept-ykro (Eticovo) and infliximab-abda, adding 2 TNF inhibitor biosimilars to US options for inflammatory diseases.
HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.
DAX-044 aims to confine IL-12 activity to tumors and avoid the toxicity that has limited IL-12 therapy, with phase 1 testing expected in 2027.
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Advertisement
Advertisement
Trending on BioPharm International
1
Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule
2
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
3
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
4
Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion
5